Hemorrhagic cerebral complications on the background of therapy with clopidogrel in patients with ischemic stroke with CYP2C19*17 polymorphous carriage: a clinical case

Objective. To demonstrate on a clinical example the importance of conducting pharmacogenetic testing in patients with ischemic stroke receiving clopidogrel in order to identify the polymorphic carriage of CYP2C19*17 (C806T, rs12248560). Materials and methods. A clinical and laboratory examination of 121 patients with ischemic stroke was carried out, the CYP2C19*17 polymorphism (C806T, rs12248560) associated with an increase in the effectiveness of clopidogrel, low residual platelet reactivity, and an increased risk of bleeding was determined. Carriage of polymorphic markers was determined by real-time polymerase chain reaction. Results and conclusion. In two patients (1.7 %), carriers of polymorphic markers CYP2C19*17, hemorrhagic cerebrovascular complications were detected on the background of clopidogrel. Gastrointestinal bleeding, as well as other complications of antiplatelet therapy, are not registered in practice

1. Zhao Y, Yang S, Wu M. Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases. Front Pharmacol. 2021 Dec 17;12:794417. DOI: 10.3389/fphar.2021.794417

2. Kang HG, Lee SJ, Heo SH, Chang DI, Kim BJ. Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment. Front Neurol. 2021 Aug 10;12:652416. DOI: 10.3389/fneur.2021.652416

3. Navarese EP, Khan SU, Kołodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation. 2020 Jul 14;142(2):150–160. DOI: 10.1161/CIRCULATIONAHA.120.046786

4. Amarenco P, Sissani L, Labreuche J, et al. PERFORM and PRoFESS Committees and Investigators. The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovasc Dis. 2017;43(3-4):145–151. DOI: 10.1159/000453459

5. Zhao Y, Yang W, Tan Z, Wang W, Xiao W, Zeng J, Xu A. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke Vasc Neurol. 2017 Jun 21;2(3):118–123. DOI: 10.1136/svn-2017-000072

6. Takahashi W, Moriya Y, Mizuma A, et al. Cerebral microbleeds on T2*-weighted images and hemorrhagic transformation after antithrombotic therapies for ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:e528–e532. DOI: 10.1016/j.jstrokecerebrovasdis.2013.05.037

7. Wang DN, Hou XW, Yang BW, et al. Quantity of Cerebral Microbleeds, Antiplatelet Therapy, and Intracerebral Hemorrhage Outcomes: A Systematic Review and Meta-analysis. J Stroke Cerebrovasc Dis. 2015;24(12):2728–2737. DOI: 10.1016/j.jstrokecerebrovasdis.2015.08.003

8. Wilson D, Charidimou A, Ambler G, Fox ZV, et al. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA. Neurology. 2016;87(14):1501–1510. DOI: 10.1212/WNL.0000000000003183

9. Zhang YJ, Li MP, Tang J, Chen XP. Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int J Environ Res Public Health. 2017 Mar 14;14(3):301. DOI: 10.3390/ijerph14030301

10. Verma SS, Bergmeijer TO, Gong L, et al. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clin Pharmacol Ther. 2020 Nov;108(5):1067– 1077. DOI: 10.1002/cpt.1911